At ViiV Healthcare our goal is simple; to end the HIV epidemic. Over the last 40 years there have been incredible advances in the development of effective HIV treatments that allow people living with HIV (PLHIV) to suppress their virus to undetectable levels.
However, the needs of PLHIV change over time, and we‘re exploring new ways of treating and preventing HIV through new mechanisms of action and drug delivery.
We have a number of potential medicines in development for the treatment and prevention of HIV:
Clinical development pipeline
Compound number / Generic name / Brand name |
Indication |
Phase |
Mode of action / Vaccine type |
|---|---|---|---|
| VH3810109 ✝^ | HIV |
Phase II |
HIV broadly neutralizing antibody |
| GSK3640254 ^ | HIV | Phase II | HIV maturation inhibitor |
| GSK1265744 ^ cabotegravir |
HIV (400 mg/ml formulation) | Phase I | HIV integrase inhibitor |
| VH3739937 ^ | HIV | Phase I | HIV maturation inhibitor |
| VH4004280 ^ | HIV | Phase I | HIV capsid protein inhibitor |
Compassionate use
Read more about our commitment to compassionate use within HIV clinical trials
.jpg)
YOU MAY ALSO BE INTERESTED IN
An exciting and relatively new area of research in the development of next generation HIV treatments involves broadly neutralising antibodies (bNAbs).
Opened in late 2017, our Branford research facility in Connecticut, USA, hosts more than 30 specialist scientists working across the spectrum of medical development, from early-stage discovery through to development research.
We’ve got more than 50 active collaborations worldwide with pharmaceutical and biotechnology companies, government agencies, academic institutions and not-for-profit organisations to broaden our capabilities and enhance our performance.
